European Medicines Agency Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application For Accelerated Assessment

Author: Benzinga Newsdesk | November 27, 2023 03:34am

Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has performed a technical validation of the Marketing Authorization Application (MAA) for Valneva's single-shot chikungunya vaccine candidate VLA1553 and has determined that all essential regulatory elements required for scientific assessment were included in the application. The MAA was granted accelerated assessment1 last month by EMA's Committee for Medicinal Products for Human Use (CHMP) based on the vaccine candidate's "major interest for public health and therapeutic innovation.

Posted In: PARIS:VLA VALN